Katherine Morel

Dr Katherine Morel

Postdoctoral Researcher - SAiGENCI

South Australian Immunogenomics Cancer Institute

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.


Dr. Katherine Morel is a Research Fellow in the South Australian Immunogenomics Cancer Institute (SAiGENCI) and Dame Roma Mitchell Cancer Research Laboratories (DRMCRL) at the University of Adelaide. in 2017, Dr. Morel was awarded her PhD from Flinders University in Adelaide, South Australia. Her doctoral research was carried out under the supervision of Prof. Pamela Sykes and focused on investigating the use of the anti-inflammatory compound parthenolide in the treatment and prevention of prostate cancer. Following the completion of her PhD studies, Dr. Morel continued her training as a Postdoctoral Research Fellow at the Dana-Farber Cancer Institute (DFCI), Harvard University in Boston, Massachusetts. At DFCI, Dr. Morel's research interests focused on genetic drivers of aggressive prostate cancer and identifying and utilising novel therapeutic approaches to target these genetic perturbations. This research utilised unique GEM and 3D organoid models of prostate cancer together with the latest techniques in genomics and proteomics. In 2022, Dr. Morel returned to Adelaide to continue her research into prostate cancer at the University of Adelaide.

  • Journals

    Year Citation
    2024 German, B., Singh, J. N., Fonseca, M. A., Burkhart, D. L., Sheahan, A., Bergom, H., . . . Ellis, L. (2024). MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer.. bioRxiv.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Data from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S2 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S1 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S3 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Table S2 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Data from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Table S2 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Table S1 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S1 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S4 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S2 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Table S1 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S4 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S3 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    DOI
    2021 Morel, K. L., Sheahan, A. V., Burkhart, D. L., Baca, S. C., Boufaied, N., Liu, Y., . . . Ellis, L. (2021). EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature Cancer, 2(4), 444-456.
    DOI Scopus109 WoS90 Europe PMC81
    2021 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2021). NF-κB blockade with oral administration of dimethylaminoparthenolide, delays prostate cancer resistance to androgen receptor inhibition and inhibits AR variants. Mol Cancer Res, 19(7), 1137-1145.
    DOI Scopus7 WoS5 Europe PMC5
    2020 Burkhart, D. L., Morel, K. L., Wadosky, K. M., Labbe, D. P., Galbo, P. M., Dalimov, Z., . . . Ellis, L. (2020). Evidence that EZH2 deregulation is an actionable therapeutic target for prevention of prostate cancer. Cancer Prevention Research, 13(12), 979-988.
    DOI Scopus3 WoS3 Europe PMC3
    2020 VanDeusen, H. R., Ramroop, J. R., Morel, K. L., Bae, S. Y., Sheahan, A. V., Sychev, Z., . . . Drake, J. M. (2020). Targeting RET kinase in neuroendocrine prostate cancer. Molecular Cancer Research, 18(8), 1176-1188.
    DOI Scopus25 WoS17 Europe PMC19
    2019 Tran, L. N. K., Kichenadasse, G., Morel, K. L., Lavranos, T. C., Klebe, S., Lower, K. M., . . . Sykes, P. J. (2019). The combination of metformin and valproic acid has a greater anti-tumoral effect on prostate cancer growth in vivo than either drug alone. In Vivo, 33(1), 99-108.
    DOI Scopus12 Europe PMC8
    2019 Morel, K. L., Ormsby, R. J., Klebe, S., Sweeney, C. J., & Sykes, P. J. (2019). DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo. Radiation research, 192(2), 231-239.
    DOI Scopus5 WoS5 Europe PMC2
    2018 Morel, K. L., Ormsby, R. J., Solly, E. L., Tran, L. N. K., Sweeney, C. J., Klebe, S., . . . Sykes, P. J. (2018). Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clinical and Experimental Metastasis, 35(7), 649-661.
    DOI Scopus7 WoS6 Europe PMC4
    2017 Morel, K. L., Ormsby, R. J., Bezak, E., Sweeney, C. J., & Sykes, P. J. (2017). Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues in Vivo. Radiation Research, 187(5), 501-512.
    DOI Scopus29 WoS27 Europe PMC16
    2017 Tran, L. N., Kichenadasse, G., Butler, L. M., Centenera, M. M., Morel, K. L., Ormsby, R. J., . . . Sykes, P. J. (2017). The combination of metformin and valproic acid induces synergistic apoptosis in the presence of p53 and androgen signaling in prostate cancer. Molecular cancer therapeutics, 16(12), 2689-2700.
    DOI Scopus25 WoS22 Europe PMC14
    2014 Newman, M., Sykes, P., Blyth, B., Bezak, E., Lawrence, M., Morel, K., & Ormsby, R. (2014). A single whole-body low dose X-irradiation does not affect L1, B1 and IAP repeat element DNA methylation longitudinally. PLoS One, 9(3), e93016-1-e93016-10.
    DOI Scopus13 WoS11 Europe PMC10
    2014 Newman, M., Sykes, P., Blyth, B., Bezak, E., Lawrence, M., Morel, K., & Ormsby, R. (2014). The methylation of DNA repeat elements is sex-dependent and temporally different in response to X radiation in radiosensitive and radioresistant mouse strains. Radiation Research, 181(1), 65-75.
    DOI Scopus17 WoS17 Europe PMC15
  • Book Chapters

    Year Citation
    2019 Burkhart, D. L., Morel, K. L., Sheahan, A. V., Richards, Z. A., & Ellis, L. (2019). The Role of RB in Prostate Cancer Progression. In S. M. Dehm, & D. J. Tindall (Eds.), Advances in Experimental Medicine and Biology (Vol. 1210, pp. 301-318). SPRINGER INTERNATIONAL PUBLISHING AG.
    DOI Scopus12 WoS10 Europe PMC6
  • Conference Papers

    Year Citation
    2019 Hamid, A., Werner, L., Huang, Y., Vicier, C., Morel, K., Ellis, L., & Sweeney, C. (2019). Prognostic impact of tristetraprolin (TTP) and PTEN loss and assessment of associated immune infiltrates in localized prostate cancer (PrCa).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
    DOI
    2017 Tran, L. N. K., Kichenadasse, G., Ormsby, R. J., Morel, K. L., Butler, L. M., Centenera, M. M., & Sykes, P. J. (2017). COMBINATION OF METFORMIN AND SODIUM VALPROATE FOR PROSTATE CANCER: A RAPID APPROACH FROM BENCH TO CLINICAL TRIAL.. In JOURNAL OF UROLOGY Vol. 197 (pp. E1108-E1109). Boston, MA: ELSEVIER SCIENCE INC.
    DOI
    2016 Tran, L. N. K., Kichenadasse, G., Morel, K. L., Ormsby, R. J., Butler, L. M., Centenera, M. M., & Sykes, P. J. (2016). Combination of metformin and valproic acid in personalized prostate cancer treatment: the role of p53 and androgen receptor signaling. In CANCER RESEARCH Vol. 76 (pp. 4 pages). New Orleans, LA: AMER ASSOC CANCER RESEARCH.
    2013 Morel, K., Ormsby, R., Bezak, E., Tilley, W., Lawrence, M., & Sykes, P. (2013). Parthenolide as a selective radiosensitiser in the treatment and prevention of prostate cancer. In BJU International Vol. 112 (pp. 45). Melbourne: Wiley.
  • Conference Items

    Year Citation
    2022 Sweeney, C. J., Morel, K., Hamid, A., & Ellis, L. (2022). Combined loss of tristetraprolin (TTP) and PTEN leads to aggressive prostate cancer and hypersensitivity to nuclear factor kappa B (NFkB) inhibition.. Poster session presented at the meeting of CANCER RESEARCH. LA, New Orleans: AMER ASSOC CANCER RESEARCH.
    2022 Sweeney, C. J., Morel, K., Hamid, A., & Ellis, L. (2022). Combined loss of tristetraprolin (TTP) and PTEN leads to aggressive prostate cancer and hypersensitivity to nuclear factor kappa B (NFkB) inhibition. Poster session presented at the meeting of CANCER RESEARCH. LA, New Orleans: AMER ASSOC CANCER RESEARCH.

CURRENT FELLOWSHIPS

  • Prostate Cancer Foundation (US) Young Investigator Award. Morel KL. Modulation of oxidative stress responses to augment prostate cancer radiation therapy. 2024-2026. $346,707

PREVIOUS FELLOWSHIPS

  • US Department of Defense Prostate Cancer Research Program Early Investigator Research Award. Morel KL. Targeting EZH2 for Novel Combination Therapeutic Strategies in Aggressive Variant Prostate Cancer. 2019-2021. $USD 200,000.
  • Position: Postdoctoral Researcher - SAiGENCI
  • Phone: 83137336
  • Email: katherine.morel@adelaide.edu.au
  • Campus: NorthTerrace
  • Building: Adelaide Health and Medical Sciences, floor 8
  • Org Unit: South Australian Immunogenomics Cancer Institute

Connect With Me
External Profiles